A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study

AIM: To compare the long‐term efficacy of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors as second‐line drugs after metformin for patients not at high risk of atherosclerotic cardiovascular disease (ASCVD). MATERIALS AND METHODS: In a 52‐week randomized open‐label t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitazawa, Masaru, Katagiri, Takashi, Suzuki, Hiromi, Matsunaga, Satoshi, H Yamada, Mayuko, Ikarashi, Tomoo, Yamamoto, Masahiko, Furukawa, Kazuo, Iwanaga, Midori, Hatta, Mariko, Fujihara, Kazuya, Yamada, Takaho, Tanaka, Shiro, Sone, Hirohito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898334/
https://www.ncbi.nlm.nih.gov/pubmed/33416200
http://dx.doi.org/10.1111/dom.14288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898334/
https://www.ncbi.nlm.nih.gov/pubmed/33416200
http://dx.doi.org/10.1111/dom.14288

Ejemplares similares